VERV - Verve Therapeutics, Inc. Stock Price, Fair Value and News

6.03USD-0.33 (-5.19%)Market Closed

Market Summary

USD6.03-0.33

Market Closed

-5.19%

VERV Stock Price

View Fullscreen

VERV RSI Chart

VERV Valuation

Market Cap

534.0M

Price/Earnings (Trailing)

-2.71

Price/Sales (Trailing)

33.27

EV/EBITDA

-2.02

Price/Free Cashflow

-3.56

VERV Price/Sales (Trailing)

VERV Profitability

EBT Margin

-1224.05%

Return on Equity

-33.76%

Return on Assets

-26.88%

Free Cashflow Yield

-28.07%

VERV Fundamentals

VERV Revenue

Revenue (TTM)

16.0M

Rev. Growth (Yr)

305.63%

Rev. Growth (Qtr)

10.71%

VERV Earnings

Earnings (TTM)

-196.8M

Earnings Growth (Yr)

6.23%

Earnings Growth (Qtr)

-0.79%

Breaking Down VERV Revenue

52 Week Range

5.8921.42

(Low)(High)

Last 7 days

3.6%

Last 30 days

-27.2%

Last 90 days

-48.6%

Trailing 12 Months

-65.4%

How does VERV drawdown profile look like?

VERV Financial Health

Current Ratio

19.82

VERV Investor Care

Shares Dilution (1Y)

35.58%

Diluted EPS (TTM)

-2.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	16.0M	0	0	0
2023	4.4M	6.8M	9.3M	11.8M
2022	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Verve Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	nickerson joan	sold	-12,475	8.24	-1,514	chief administrative officer
Apr 01, 2024	nickerson joan	acquired	-	-	3,315	chief administrative officer
Dec 01, 2023	yeshwant krishna	bought	18,000,000	10.00	1,800,000	-
Nov 29, 2023	dorval allison	acquired	-	-	1,875	chief financial officer
Nov 29, 2023	dorval allison	sold	-6,343	11.45	-554	chief financial officer
Sep 18, 2023	adelman burt a	gifted	-	-	37,168	-
Sep 18, 2023	adelman burt a	gifted	-	-	-37,168	-
Aug 11, 2023	adelman burt a	gifted	-	-	266,258	-
Aug 11, 2023	adelman burt a	gifted	-	-	-266,258	-
Dec 14, 2022	bellinger andrew	acquired	103,320	2.87	36,000	cso & cmo

Which funds bought or sold VERV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	KBC Group NV	new	-	23,000	23,000	-%
May 08, 2024	ProShare Advisors LLC	added	30.97	46,644	235,002	-%
May 08, 2024	Sandy Spring Bank	added	18.18	3,860	34,528	-%
May 08, 2024	Bell Investment Advisors, Inc	sold off	-100	-586	-	-%
May 08, 2024	US BANCORP \DE\	unchanged	-	-215	4,329	-%
May 08, 2024	TD Asset Management Inc	added	27.2	138,927	794,888	-%
May 08, 2024	Russell Investments Group, Ltd.	added	1,700	5,177	5,498	-%
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	added	1.59	10,271	212,262	-%
May 08, 2024	Entropy Technologies, LP	reduced	-59.33	-320,907	202,958	0.02%
May 08, 2024	PROFUND ADVISORS LLC	added	35.24	198,553	887,064	0.04%

Are Funds Buying or Selling VERV?

Are funds buying VERV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VERV

No. of Funds

Unveiling Verve Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.81%	5,471,930	SC 13G/A
Jan 29, 2024	ark investment management llc	8.74%	7,025,116	SC 13G/A
Jan 29, 2024	blackrock inc.	5.6%	4,435,481	SC 13G
Jan 23, 2024	state street corp	4.81%	3,866,764	SC 13G/A
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Dec 11, 2023	gv 2017, l.p.	7.6%	6,108,442	SC 13G/A
Feb 14, 2023	singer james r	8.1%	5e+06	SC 13G/A
Feb 14, 2023	casdin capital, llc	3.7%	2,290,571	SC 13G/A
Feb 13, 2023	arch venture fund x, l.p.	-	0	SC 13G/A
Feb 10, 2023	blackrock inc.	5.8%	3,594,074	SC 13G

Recent SEC filings of Verve Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	8-K	Current Report
Feb 27, 2024	8-K	Current Report
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Verve Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.2B	2.0B	-2.86%	-28.22%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	-0.76%	-10.51%	28.42	4.5	60.38%	-34.49%
NVAX	627.0M	983.7M	1.36%	-50.17%	-1.15	0.64	-50.36%	17.16%
CRBP	467.5M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	260.8M	4.9M	-4.04%	14.81%	-1.93	53.59	-54.97%	51.71%
IBIO	6.4M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Verve Therapeutics, Inc. News

Latest updates

Verve Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Revenue	10.7%	5,695,000	5,144,000	3,117,000	2,093,000	1,404,000	1,166,500	929,000
Operating Expenses	5.8%	62,539,000	59,092,000	55,451,000	60,676,000	59,663,000	48,722,000	44,789,000
S&GA Expenses	-100.0%	-	12,281,000	11,686,000	13,416,000	12,553,000	11,438,500	9,592,000
R&D Expenses	3.3%	48,376,000	46,811,000	43,765,000	47,260,000	47,110,000	37,283,500	35,197,000
EBITDA Margin	28.2%	-11.87	-16.53	-20.17	-27.43	-39.98	-79.61	-
Income Taxes	400.0%	100,000	20,000	67,000	200,000	-	53,000	-
Earnings Before Taxes	-0.6%	-48,630,000	-48,320,000	-45,691,000	-53,807,000	-51,975,000	-41,032,000	-45,190,000
EBT Margin	28.0%	-12.24	-16.99	-20.69	-28.03	-40.76	-81.06	-
Net Income	-0.8%	-48,736,000	-48,352,000	-45,758,000	-53,983,000	-51,975,000	-41,085,000	-45,190,000
Net Income Margin	27.9%	-12.26	-17.02	-20.72	-28.07	-40.77	-81.09	-
Free Cashflow	-1.5%	-43,515,000	-42,865,000	-12,872,000	-50,624,000	-52,471,000	-37,860,000	-31,812,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-2.7%	732	753	612	589	634	679	673	324	349	384	411	427	78.00
Current Assets	-2.8%	620	638	498	473	518	563	562	299	329	367	394	420	74.00
Cash Equivalents	-27.7%	149	206	78.00	70.00	84.00	115	277	73.00	91.00	70.00	148	387	9.00
Net PPE	-6.6%	21.00	23.00	21.00	21.00	21.00	19.00	15.00	12.00	11.00	7.00	7.00	6.00	4.00
Liabilities	-2.5%	149	153	152	124	125	128	125	28.00	18.00	27.00	26.00	21.00	17.00
Current Liabilities	-15.4%	31.00	37.00	35.00	33.00	34.00	35.00	29.00	26.00	15.00	22.00	20.00	9.00	7.00
Shareholder's Equity	-2.7%	583	600	460	465	509	551	548	296	331	357	385	405	-
Retained Earnings	-9.0%	-593	-544	-495	-450	-396	-344	-303	-257	-217	-186	-155	-132	-66.54
Additional Paid-In Capital	2.9%	1,177	1,143	957	916	906	896	852	555	549	544	540	538	3.00
Shares Outstanding	2.3%	84.00	82.00	64.00	62.00	62.00	62.00	57.00	49.00	49.00	27.00	20.00	8.00	-
Float	-	-	-	-	940	-	-	-	557,600	-	-	-	2,185	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-5.9%	-43,082	-40,680	-11,811	-47,962	-49,096	-32,892	-29,175	-26,758	-33,507	-28,043	-21,355	-13,341	-15,141	-14,975	-6,324	-	-
Share Based Compensation	11.7%	10,341	9,254	8,825	9,013	8,024	6,704	5,920	5,650	4,203	2,758	2,293	1,351	670	442	213	-	-
Cashflow From Investing	-368.1%	-41,632	-8,893	-11,834	33,025	15,392	-168,313	-55,516	7,782	60,092	-56,985	-212,316	18,489	11,714	11,887	-2,718	-	-
Cashflow From Financing	-87.2%	22,734	177,383	31,923	1,233	2,038	39,598	288,408	445	505	1,224	-867	282,901	93,831	8.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VERV Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaborations Revenue	$ 5,695	$ 1,404
Operating expenses:
Research and development	48,376	47,110
General and administrative	14,163	12,553
Total operating expenses	62,539	59,663
Loss from operations	(56,844)	(58,259)
Other income:
Change in fair value of success payment liability	78	738
Interest and other income, net	8,136	5,546
Total other income, net	8,214	6,284
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total	(48,630)	(51,975)
Provision for income taxes	$ (106)	$ 0
Net loss per common share , basic	$ (0.59)	$ (0.84)
Net loss per common share , diluted	$ (0.59)	$ (0.84)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic	83,132,960	61,787,403
Weighted-average common shares used in net loss per share attributable to common stockholders, diluted	83,132,960	61,787,403
Comprehensive Loss:
Net loss	$ (48,736)	$ (51,975)
Other comprehensive (loss) gain:
Unrealized (loss) gain on marketable securities	(772)	457
Comprehensive loss	$ (49,508)	$ (51,518)

VERV Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 144,200	$ 206,180
Marketable securities	462,167	417,770
Collaboration receivable	5,767	5,897
Prepaid expenses and other current assets	8,192	8,102
Total current assets	620,326	637,949
Property and equipment, net	21,024	22,505
Restricted cash	4,774	4,774
Operating lease right-of-use assets	83,527	85,295
Other long term assets	2,706	2,165
Total assets	732,357	752,688
Current liabilities:
Accounts payable	3,049	6,636
Accrued expenses	16,552	20,178
Deferred revenue, current	1,473	0
Lease liability, current portion	10,220	10,192
Total current liabilities	31,294	37,006
Long-term lease liability	63,454	64,715
Success payment liability	2,642	2,720
Deferred revenue, non-current	51,733	48,556
Other long term liabilities	165	189
Total liabilities	149,288	153,186
Commitments and contingencies (See Note 7 and Note 8)
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized, 83,819,862 and 81,969,693 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	84	82
Additional paid-in capital	1,176,526	1,143,453
Accumulated other comprehensive income (loss)	(500)	272
Accumulated deficit	(593,041)	(544,305)
Total stockholders equity	583,069	599,502
Total liabilities and stockholders' equity	$ 732,357	$ 752,688

About Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Sekar Kathiresan M.D.
WEBSITE	vervetx.com
INDUSTRY	Biotechnology
EMPLOYEES	204

Verve Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Verve Therapeutics, Inc.? What does VERV stand for in stocks?

VERV is the stock ticker symbol of Verve Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Verve Therapeutics, Inc. (VERV)?

As of Thu May 09 2024, market cap of Verve Therapeutics, Inc. is 534.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERV stock?

You can check VERV's fair value in chart for subscribers.

What is the fair value of VERV stock?

You can check VERV's fair value in chart for subscribers. The fair value of Verve Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Verve Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VERV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Verve Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VERV is over valued or under valued. Whether Verve Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Verve Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERV.

What is Verve Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, VERV's PE ratio (Price to Earnings) is -2.71 and Price to Sales (PS) ratio is 33.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VERV PE ratio will change depending on the future growth rate expectations of investors.